Table S2. Characteristics of the experimental groups.

Group, n	Drugs	Administration route	Dose	Administration regimen	Cumulative dose	Duration
Control (n = 15)	0.9% sodium chloride solution	i.p.	1 ml	6 times every two days	6 ml	2.5 weeks
DOX (n = 15)	doxorubicin	i.p.	1,67 mg/kg	6 times every two days	10 mg/kg	2.5 weeks
NR+DOX (n = 15)	NR + doxorubicin	i.v. + i.p.	300 mg/kg + 1,67 mg/kg	*Combined mode* 6 times every two days: i.v. NR → 30 min → i.p. doxorubicin	1800 mg/kg + 10 mg/kg	2.5 weeks
NR/NR+DOX (n = 15)	NR + doxorubicin	i.v. + i.p.	300 mg/kg + 1,67 mg/kg	*Preventive mode* 3 times every two days i.v. NR → i.p. doxorubicin 6 times alternating every other time with NR (3 times)	1800 mg/kg + 10 mg/kg	3.5 weeks

DOX, doxorubicin; i.p., intraperitoneal administration; i.v., intravenous administration; NR, nicotinamide riboside. 10mg/kg of doxorubicin in rats is equivalent to 1.6mg/kg in humans (HED). 1800 mg/kg NR in rats is equivalent to 290.3 mg/kg in humans (HED).